Clinical trialNCT01500200CompletedPhase 2Interventional

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

SponsorAlkermes, Inc.Enrollment142Major Depressive Disorder

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Richard Leigh-Pemberton, MD
Alkermes, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Alkermes Investigational Site
Tucson, Arizona, United States
Alkermes Investigational Site
Oceanside, California, United States
Alkermes Investigational Site
Santa Ana, California, United States
Alkermes Investigational Site
Torrance, California, United States
Alkermes Investigational Site
Fort Myers, Florida, United States
Alkermes Investigational Site
Lauderhill, Florida, United States
Alkermes Investigational Site
Leesburg, Florida, United States
Alkermes Investigational Site
North Miami, Florida, United States
Alkermes Investigational Site
St. Petersburg, Florida, United States
Alkermes Investigational Site
Atlanta, Georgia, United States
Alkermes Investigational Site
Hoffman Estates, Illinois, United States
Alkermes Investigational Site
Baltimore, Maryland, United States
Alkermes Investigational Site
Boston, Massachusetts, United States
Alkermes Investigational Site
Haverhill, Massachusetts, United States
Alkermes Investigational Site
Berlin, New Jersey, United States
Alkermes Investigational Site
Brooklyn, New York, United States
Alkermes Investigational Site
New York, New York, United States
Alkermes Investigational Site
Canton, Ohio, United States
Alkermes Investigational Site
Dayton, Ohio, United States
Alkermes Investigational Site
Oklahoma City, Oklahoma, United States
Alkermes Investigational Site
Philadelphia, Pennsylvania, United States
Alkermes Investigational Site
Charleston, South Carolina, United States
Alkermes Investigational Site
Austin, Texas, United States
Alkermes Investigational Site
Dallas, Texas, United States
Alkermes Investigational Site
Houston, Texas, United States
Alkermes Investigational Site
San Antonio, Texas, United States
Alkermes Investigational Site
Bellevue, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2011
Primary completion: 31 Mar 2013
Completion: 31 Mar 2013
Last update posted: 21 May 2019
Registered enrollment: 142
Registry id: NCT01500200

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.